Bold shift in cancer diagnostics is underway as a new blood-based test technology promises to replace invasive tissue biopsies, signaling a potential seismic change in how cancer is detected and managed. This pivot is detailed in the report titled "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029", now added to ResearchAndMarkets.com.
The publication thoroughly analyzes opportunities across screening, diagnosis, therapy selection, and monitoring for minimal residual disease. It provides price and volume projections broken down by cancer type, delivering actionable insights for investors, healthcare providers, and policy makers alike.
At the heart of this revolution are technologies such as Circulating Tumor Cells, Cell-Free DNA, and Exosomes. These advances are driving a new generation of widespread cancer screening tests and opening up opportunities while presenting challenges. The report outlines growth expectations and estimates the market’s potential size as these technologies reshape the industry landscape.
In vitro blood testing is accelerating a new era in cancer diagnostics, outpacing traditional methods with the ability to identify diseases from blood samples. The analysis highlights the current growth phase of the market and forecasts its future impact on healthcare, including anticipated market size over the next five years with country-, cancer type-, and usage-specific detail: screening, diagnosis, therapy selection, and recurrence monitoring.
The findings include granular breakdowns across 15 countries and 4 major regions, categorized by cancer types such as Lung, Breast, Colorectal, Prostate, and Cervical. It also covers nuances within Screening/Early Detection, Diagnostic, Therapy Monitoring, and Recurrence Monitoring segments. Whether assessing investment opportunities or conducting valuations, the report provides data to approach the market with confidence, leveraging the latest insights for strategic planning.
A forward-looking five-year forecast equips stakeholders with essential guidance for navigating the complex, evolving landscape of cancer diagnostics technology and its transformative impact on global healthcare systems.
Companies Featured
- Abbott Laboratories
- AccuraGen Inc.
- Acuamark Diagnostics
- Admera Health, LLC
- Agilent
- Amoy Diagnostics Co., Ltd.
- Anchor Dx
- ANGLE plc
- Applied DNA Sciences
- ARUP Laboratories
- AVIVA Systems Biology
- Baylor Miraca Genetics Laboratories
- Beckman Coulter Diagnostics (Danaher)
- Becton, Dickinson and Company
- Berkley Lights
- BGI Genomics Co. Ltd
- BillionToOne
- Bio-Rad Laboratories, Inc
- Bio-Techne
- Bioarray Genetics
- Biocartis
- Biocept, Inc.
- Biodesix Inc.
- BioFluidica
- Biolidics Ltd
- bioMerieux Diagnostics
- Bioneer Corporation
- Bioview
- Burning Rock
- Cardiff Oncology
- CareDx
- Caris Molecular Diagnostics
- CellCarta
- CellMax Life
- Cepheid (Danaher)
- Circulogene
- Cizzle Biotech
- Clearbridge Biomedics
- Clinical Genomics
- Cytolumina Technologies Corp.
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Dxcover
- Element Biosciences
- Enzo Biochem
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Exact Sciences
- Fluxion Biosciences (Cell Microsystems)
- Freenome
- Fyr Diagnostics
- GeneFirst Ltd.
- Genetron Holdings
- GILUPI Nanomedizin
- Guardant Health
- HansaBiomed
- Haystack Oncology (Quest Dx)
- iCellate
- ICON PLC
- Illumina
- Incell Dx
- Inivata
- INOVIQ
- Invitae Corporation
- J&J Innovative Medicine
- Lucence Health
- Lunglife AI Inc
- MDNA Life SCIENCES, Inc.
- MDx Health
- Menarini Silicon Biosystems
- Mesa Laboratories, Inc.
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Myriad Genetics
- Nanostring
- NantHealth, Inc.
- Natera
- NeoGenomics
- Novogene
- On-Chip Biotechnologies
- Oncimmune
- Oncocyte
- OncoDNA
- Oxford Nanopore Technologies
- PamGene
- Panagene
- Personalis
- PGDx (Labcorp)
- PrecisionMed
- Predicine
- Predictive Oncology
- Prenetics
- Promega
- Qiagen
- Rarecells SAS
- RareCyte
- Revvity
- Roche Diagnostics
- Saga Diagnostics
- Screencell
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc.
- Singular Genomics
- Standard BioTools
- Stilla Technologies
- Superfluid Dx
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific
- Todos Medical
- Ultima Genomics
- Veracyte
- VolitionRX
- Vortex Biosciences
For more information about this report, see https://www.researchandmarkets.com/r/uso200.
About ResearchAndMarkets.com
ResearchAndMarkets.com is a leading global source for international market research reports and market data. It provides up-to-date information on international and regional markets, key industries, top companies, new products, and emerging trends.
